Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $190

Chardan Capital maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $150 to $190.

Benzinga · 12/19/2019 12:48

Chardan Capital maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $150 to $190.